Article
Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer.
Nature communications - 30 Mar 2021
Baca Sylvan C, Takeda David Y, Seo Ji-Heui, Hwang Justin, Ku Sheng Yu, Arafeh Rand, Arnoff Taylor, Agarwal Supreet, Bell Connor, O'Connor Edward, Qiu Xintao, Alaiwi Sarah Abou, Corona Rosario I, Fonseca Marcos A S, Giambartolomei Claudia, Cejas Paloma, Lim Klothilda, He Monica, Sheahan Anjali, Nassar Amin, Berchuck Jacob E, Brown Lisha, Nguyen Holly M, Coleman Ilsa M, Kaipainen Arja, De Sarkar Navonil, Nelson Peter S, Morrissey Colm, Korthauer Keegan, Pomerantz Mark M, Ellis Leigh, Pasaniuc Bogdan, Lawrenson Kate, Kelly Kathleen, Zoubeidi Amina, Hahn William C, Beltran Himisha, Long Henry W, Brown Myles, Corey Eva, Freedman Matthew L
Abstract excerpt
Lineage plasticity, the ability of a cell to alter its identity, is an increasingly common mechanism of adaptive resistance to targeted therapy in cancer. An archetypal example is the development of neuroendocrine prostate cancer (NEPC) after treatment of prostate adenocarcinoma (PRAD) with inhibitors of androgen signaling. NEPC is an aggressive variant of prostate cancer that aberrantly expresses genes...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.